The Next Best Value in Biotech is Here

Take a look at Glucose Health, Inc. (OTC Pink: GLUC)

58

Kiplinger released an article in July titled “5 Booming Biotech Stocks to Buy

It starts off by stating that these stocks are already up over 30% but still have plenty of upside to spare.  It references the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB), but which is flat since the article was released.  

It’s “5 Booming Biotech Stocks to Buy” are:

  1. Regeneron Pharmaceuticals (NASDAQ: REGN)

Thanks to strategic partnerships with Sanofi (SNY) and Bayer (BAYRY), Regeneron has ample and expanding exposure to Europe and other international markets.

  • Exelixix (NASDAQ: EXEL) 

Its top products, Cometriq and Cabometyx, are both based on Exelixis’s flagship compound, cabozantinib; the latter is the market-leading thyroid cancer medicine.

  • Vertex Pharmaceuticals (NASDAQ: VRTX) 

The company’s flagship product is Trikafta, its new cystic fibrosis (CF) drug that recently launched in the U.S.

  • Genmab (NASDAQ: GMAB)

Their monoclonal antibody-based medicine continues to gain market share in Europe and the U.S. with the help of agreements with Seattle Genetics (NASDAQ: SGEN) and BioNTech (NASDAQ: BNTX).

  • Emerging BioSolutions (NYSE: EBS) 

This is a quickly growing biopharmaceutical company focusing on novel vaccines, treatments, medical devices and other medical countermeasures to tackle public health threats.

Outside of the article, there is an emerging company that needs to be on your radar. 

Take a look at Glucose Health, Inc. (OTC Pink: GLUC).  The Company manufacturers specialized nutritional beverages for the diabetic-adult consumer under the registered trademark GLUCODOWN®. GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.

Glucose GLUC

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand for GLUCODOWN® with 2nd quarter fiscal 2020 revenues increasing by 186% compared to the previous period – Q2 2020 revenues were just short of tripling 2nd quarter 2019 revenues.

What are the sales of this company going to look like when the latest GLUCODOWN® sales numbers from Amazon and Walmart come on the books during Q3 and Q4? 

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list. 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated eight thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here https://emerginggrowth.com/4582-6827465/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.

Add a Comment to this Post

comments